文献速递类风湿关节炎

类风湿关节炎试验安慰剂/标准治疗臂不良事件报告率与ACR应答的地区差异

Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究基于TransCelerate数据库7项RA试验的安慰剂臂数据,将970例患者按5个地理区域分组,评估不良事件报告率与ACR应答的地区差异。结果显示第12周RFEE地区不良事件率显著低于亚洲、拉美和美国,ACR50应答仅RFEE与拉美间差异经校正后仍显著。提示RA临床试验招募时应考虑患者地区分布。

要点

  • RFEE地区第12周不良事件率显著低于亚洲、拉美和美国。
  • 美国ACR20应答最低(22%),西欧最高(43%)。
  • 仅RFEE与拉美间ACR50应答差异经校正后仍显著。

核心结论

  • 安慰剂/标准治疗臂数据显示不良事件报告率和ACR50应答率存在显著地区差异。
  • 开展RA临床试验时应考虑患者的地理区域分布,尤其在招募阶段。

研究设计与样本

  • 研究纳入TransCelerate Biopharma Inc数据库7项RA试验安慰剂臂的970例患者,分为亚洲、拉丁美洲、俄罗斯联邦与东欧(RFEE)、美国、西欧5个地理区域。
  • 采用描述性统计和全局检验评估人口学、不良事件报告率及ACR应答的差异,区域间两两比较采用错误发现率校正多重比较。

主要发现

  • 第12周不良事件率RFEE为22%,显著低于亚洲51%、拉丁美洲49%和美国53%(错误发现率校正后P<0.05)。
  • 第52周不良事件率也可见类似的地区间差异。
  • 747例有ACR数据的患者中,ACR20应答率美国最低(22%)、西欧最高(43%)。
  • ACR50应答率RFEE最低(3%)、拉丁美洲最高(15%)。
  • 错误发现率校正后,仅RFEE与拉丁美洲之间的ACR50应答差异仍显著。

临床怎么用

  • 解读RA临床试验安慰剂/标准治疗臂数据时需考虑地区差异对不良事件报告率和ACR应答的影响。
  • 设计或招募RA临床试验时,应关注患者的地理区域分布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical trials are increasingly globalized, and adverse event (AE) rates and treatment responses may differ by geographical region. This study assessed regional differences in AE reporting rates and ACR response rates (ACR20/50) in patients with RA who received placebo/standard-of-care treatment in clinical trials. METHODS: Patients from the placebo arms of 7 RA trials in the TransCelerate Biopharma Inc database were grouped into 5 geographical regions (Asia, Latin America, Russian Federation and Eastern Europe [RFEE], USA, and Western Europe). Differences in demographics, AE reporting rates and ACR response were evaluated using descriptive statistics and omnibus tests for significance; pairwise comparisons were made between regions, with false discovery rate correction for multiple comparisons. RESULTS: Among 970 patients included, week 12 AE rates were significantly lower in the RFEE than in Asia, Latin America and the USA (22% vs 51%, 49% and 53%, respectively; P < 0.05 after false discovery rate correction). Similar differences in AE rates across geographical regions were seen at week 52. Among 747 patients with ACR data, the lowest response rates were observed in the USA (ACR20, 22%) and RFEE (ACR50, 3%); the highest response rates were seen in Western Europe (ACR20, 43%) and Latin America (ACR50, 15%). Only the differences in ACR50 response between the RFEE and Latin America remained significant after false discovery rate correction. CONCLUSION: These placebo/standard-of-care arm data revealed significant regional differences in AE reporting rates and ACR50 response rates. Regional distribution of patients should be considered when conducting RA clinical trials, particularly during recruitment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Keebler D, Teng E, Chia J, et al. Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials. Rheumatology (Oxford). 2020. PMID: 32182362. doi:10.1093/rheumatology/keaa043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。